Breadcrumb Home Studies Studies Search Filter Research Area AllComplications & ComorbiditiesCureTreatmentTuberculosis Study Status AllClosed to AccrualClosed to Follow UpConcludedEnrollingIn DevelopmentOpen to AccrualParticipants Off Study and Primary Analysis CompletedPendingTemporarily Closed (Paused) to Accrual and Study Agents/Products Sort Study Number AscStudy Number Desc Submit Search Showing 17 studies. IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States DAIDS Number 38746 Research Area Treatment Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Treatment Study Status Enrolling IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Treatment Study Status Enrolling IMPAACT 2010: VESTED DAIDS Number 30129 Research Area Treatment Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2007: Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection DAIDS Number 20734 Research Area Treatment Study Status Concluded P1115: Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study DAIDS Number 11954 Research Area Cure Study Status Enrolling P1110: Safety and PK of RAL in Neonates DAIDS Number 11891 Research Area Treatment Study Status Concluded P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants DAIDS Number 11882 Research Area Treatment Study Status Closed to Follow Up P1097: Raltegravir PK Study DAIDS Number 11790 Research Area Treatment Study Status Concluded P1084s: Maternal Infant TDF Toxicity Safety DAIDS Number 10790 Research Area Complications & Comorbidities Study Status Closed to Follow Up Pagination Current page 1 Page 2 Next page Next
IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States DAIDS Number 38746 Research Area Treatment Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Treatment Study Status Enrolling
IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Treatment Study Status Enrolling
IMPAACT 2010: VESTED DAIDS Number 30129 Research Area Treatment Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2007: Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection DAIDS Number 20734 Research Area Treatment Study Status Concluded
P1115: Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study DAIDS Number 11954 Research Area Cure Study Status Enrolling
P1110: Safety and PK of RAL in Neonates DAIDS Number 11891 Research Area Treatment Study Status Concluded
P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants DAIDS Number 11882 Research Area Treatment Study Status Closed to Follow Up
P1084s: Maternal Infant TDF Toxicity Safety DAIDS Number 10790 Research Area Complications & Comorbidities Study Status Closed to Follow Up
